Page last updated: 2024-08-21

thiazoles and Acute Relapsing Multiple Sclerosis

thiazoles has been researched along with Acute Relapsing Multiple Sclerosis in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.14)	29.6817
2010's	2 (14.29)	24.3611
2020's	11 (78.57)	2.80

Authors

Authors	Studies
Burcklen, M; Freedman, MS; Havrdova, EK; Hennessy, B; Larbalestier, A; Lemle, A; Olsson, T; Pozzilli, C; Sidorenko, T; Vaclavkova, A	1
Anand, B; Annadure, RK; Arulselvan, V; Deepalam, S; Gupta, S; Ichaporia, N; Iyer, RB; John, SK; Kamath, V; Kumar, S; Mathew, T; Murgod, U; Nadig, R; Nair, SS; Neeharika, ML; Netravathi, M; Parry, G; Raghavendra, S; Reddy, YM; Renukaradhya, U; Rohatgi, A; Sarma, GRK; Satishchandra, P; Sharath Kumar, GG; Shivakumar, R; Singh, P; Singhal, BS; Surya, N; Yareeda, S	1
Burcklen, M; Kracker, H; Olsson Gisleskog, P; Pérez-Ruixo, JJ; Poggesi, I; Sidorenko, T; Valenzuela, B	1
Auer, M; Bauer, A; Berek, K; Berger, T; Bsteh, G; Deisenhammer, F; Di Pauli, F; Hegen, H; Oftring, A; Reindl, M; Rudzki, D; Zinganell, A	1
Alnaif, A; D'Souza, MS; Oiler, I	1
Kruger, TM; Ouwerkerk-Mahadevan, S; Ruixo, JJP; Thompson, CD; Valenzuela, B	1
Baldin, E; Lugaresi, A	1
Burcklen, M; D'Ambrosio, D; Fox, RJ; Freedman, MS; Havrdová, EK; Hennessy, B; Hohlfeld, R; Kappos, L; Kracker, H; Linscheid, P; Lublin, F; Montalban, X; Pirozek-Lawniczek, M; Pozzilli, C; Scherz, T; Sprenger, T; Vaclavkova, A	1
Burcklen, M; Gisleskog, PO; Pérez-Ruixo, JJ; Poggesi, I; Scherz, T; Valenzuela, B	1
Markham, A	1
Kuwabara, S; Mori, M	1
Bach, D; Berkani, O; Boster, A; Fernández, Ó; Freedman, MS; Melanson, M; Mueller, MS; Olsson, T; Pozzilli, C; Radue, EW; Sidorenko, T	1
Alcázar, A; Alvarez-Cermeño, JC; Masjuan, J; Regidor, I; Salinas, M	1

Reviews

4 review(s) available for thiazoles and Acute Relapsing Multiple Sclerosis

Article	Year
Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis. The Annals of pharmacotherapy, 2023, Volume: 57, Issue:8 Topics: Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles	2023
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical pharmacokinetics, 2023, Volume: 62, Issue:11 Topics: Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Thiazoles	2023
Ponesimod for the treatment of relapsing multiple sclerosis. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:16 Topics: Administration, Oral; Clinical Trials as Topic; Humans; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles; Treatment Outcome	2020
Ponesimod: First Approval. Drugs, 2021, Volume: 81, Issue:8 Topics: Animals; Clinical Trials, Phase III as Topic; Humans; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Sphingosine-1-Phosphate Receptors; Thiazoles	2021

Trials

5 trial(s) available for thiazoles and Acute Relapsing Multiple Sclerosis

Article	Year
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies. Neurology, 2022, 08-23, Volume: 99, Issue:8 Topics: Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Thiazoles; Treatment Outcome	2022
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:10 Topics: Adult; Crotonates; Humans; Hydroxybutyrates; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Recurrence; Thiazoles; Toluidines; Treatment Outcome	2022
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA neurology, 2021, 05-01, Volume: 78, Issue:5 Topics: Adolescent; Adult; Crotonates; Disease Progression; Female; Humans; Hydroxybutyrates; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Nitriles; Thiazoles; Toluidines; Young Adult	2021
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical pharmacokinetics, 2021, Volume: 60, Issue:9 Topics: Humans; Infant; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Thiazoles; Treatment Outcome	2021
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. Journal of neurology, neurosurgery, and psychiatry, 2014, Volume: 85, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Severity of Illness Index; Thiazoles; Young Adult	2014

Other Studies

5 other study(ies) available for thiazoles and Acute Relapsing Multiple Sclerosis

Article	Year
Ponesimod (Ponvory) for multiple sclerosis. The Medical letter on drugs and therapeutics, 2021, Aug-09, Volume: 63, Issue:1630 Topics: Administration, Oral; Crotonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Humans; Hydroxybutyrates; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Randomized Controlled Trials as Topic; Sphingosine 1 Phosphate Receptor Modulators; Thiazoles; Toluidines; United States; United States Food and Drug Administration	2021
A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis. Multiple sclerosis and related disorders, 2022, Volume: 66 Topics: Adolescent; Adult; Female; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitro Compounds; Thiazoles	2022
Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab. CNS drugs, 2022, Volume: 36, Issue:10 Topics: Biomarkers; Humans; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitro Compounds; Retrospective Studies; Thiazoles; Vascular Cell Adhesion Molecule-1	2022
Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis? Journal of neurology, neurosurgery, and psychiatry, 2014, Volume: 85, Issue:11 Topics: Female; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Thiazoles	2014
Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis. Journal of neuroimmunology, 2000, Apr-03, Volume: 104, Issue:1 Topics: Adolescent; Adult; Animals; Apoptosis; Axons; Cells, Cultured; Cerebrospinal Fluid; Coloring Agents; Humans; Metallothionein; Microscopy, Confocal; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurons; Rats; Tetrazolium Salts; Thiazoles	2000